Joshua Zeidner MD
@LeukDocJZ
Associate Prof of Med @UNC_Lineberger | Oncologist | Clinical Trialist- #AML & #MDS | Alum of Osler Residency & Hopkins Oncology | NYG & Tar Heels|Views my own
Congratulations @cedittus1 for leading this important study of high unmet need for a very rare disease. Amazing accomplishment to conduct this study in a multi-institutional effort @UNC_Lineberger 👏
Have been working w/ @Jmarksloan on this for a decade: BV-CHEP for 1L ATLL. @BrJHaem N=16 CR: 62.5% ORR: 87.5% mOS: 15.7m AlloSCT: 5 pts; mOS: NR Tox: cytopenias, mucositis, PN New consideration for aggressive ATLL. onlinelibrary.wiley.com/doi/epdf/10.11…
Great way to end an outstanding meeting on all the advances & future directions of AML & ALL @_MDEducation @doctorpemm
Fantastic conference @_MDEducation in Marina Del Rey, CA with the best colleagues and friends from across the country!
👉👉👉Wonderful interactive, engaging group with new 💡 & new discussions meeting up together at @_MDEducation #leusm #BPDCN | @jaltmanmd @sankalparoramd @GhayasIssa @NicholasShortMD ||| 🙌
Fantastic debate about sequential therapies (Harry Erba) versus Triplets (@jaltmanmd) in AML. “The coolest things come in 3’s.” Triplets are already being developed in pivotal randomized trials. Fascinating discussion panel! @_MDEducation
Fantastic presentations by @EuniceWangMD & Gus Issa on menin inhibitors (single agents & combo), biology, mechanisms of resistance and future combination strategies. Such an exciting era for AML therapy @_MDEducation
There cannot be a discussion about Transplant without the inimitable @charliecraddock who gives a wonderful and detailed overview as well as future directions of transplant and maintenance @_MDEducation
Mark Levis gives an outstanding and thoughtful presentation on biology and mechanism of relapsed/refractory disease in FLT3-ITD mutated AML @_MDEducation
An incredible overview, as always, by @sanamloghavi about the nuances in the diagnostic and molecular work up of AML. I always learn a ton from @sanamloghavi @_MDEducation
Fantastic presentation by the FLT3 guru @Daver_Leukemia on the incredible treatment advances in FLT3-mutated AML @_MDEducation
An incredible overview of the history, advances and future directions of AML therapy by @DrHKantarjian @_MDEducation AML-ALL US Focus Meeting.
Catching up with great friends and colleagues is always the highlight of meetings @_MDEducation @doctorpemm @EuniceWangMD
Always inspiring to hear @doctorpemm speak about BPDCN. Another fantastic overview by THE BPDCN guru @_MDEducation
Looking forward to working with a stellar new class of fellows @UNC_Lineberger @UNCHemeOnc
🎉 Please join us in welcoming our incredible new fellows! After a week of orientation, dinners, and getting to know one another, they officially start tomorrow. We’re so excited for all they’ll bring to our program and our patients. Let’s go! 💪🏽🩵 @UNC_SOM @UNC_Health_Care
Looking forward to this fantastic meeting next week with an all star lineup 👇
🗓 Next Week: We're just days away from the 4th Annual AML-ALL US Focus Meeting 2025, taking place July 10–12 at the Marina del Rey Marriott, CA. A huge thank you to our co-chairs for curating an outstanding agenda and world-class faculty: ▪️ @Daver_Leukemia – MD Anderson Cancer…
Fascinating results and data! Great work @TaylorJ_MD and team!
Our new paper is out @Nature_NPJ Precision Oncology! rdcu.be/eujnK With @JustinWattsMD and colleagues @SylvesterCancer we report on the first patient functionally cured by single-agent IDH1 inhibition with Olutasidenib @RigelPharma for r/r #AML @NaturePortfolio 🧵
This 👇. Never underestimate the power of hope for patients with cancer!
👏 I saw an interesting anecdote and just looked up the reference. Literally before I was born, an oncologist very succinctly and elegantly summarized how we offer hope to our patients living with cancer... these words are still true today! pubmed.ncbi.nlm.nih.gov/18750361/
Could not have done the study without Alice’s & @beatalleukemia Beat AML leadership, support and advocacy @OSUHematology 🙏
📢New hope for AML patients: A study co-authored by @OSUCCC_James Alice Mims & @beatalleukemia shows azacitidine+venetoclax+revumenib achieved an 88% response rate in newly diagnosed NPM1-mutated or KMT2A-rearranged AML @JCO_ASCO. Incredible work!🧬🩸 🔗 pubmed.ncbi.nlm.nih.gov/40504618
Thanks for highlighting our work @UNC_Lineberger @UNCDeptMedicine @LLSusa 🙏
A combination therapy that adds a new drug to the current care for newly diagnosed acute myeloid leukemia showed high rates of complete remission in an early-phase clinical trial conducted at UNC Lineberger and 11 other sites. - Read the full study here: ascopubs.org/doi/10.1200/JC…
Proud of @DPetersMD for completing his Heme/Onc fellowship and Chief year @UNC_Lineberger @UNCDeptMedicine. Beyond excited to see all that you will accomplish at Georgia Cancer Center! Of course, had to celebrate with lunch at Merritt’s (IYKYK)!
Very disappointing results from VERONA Study. We need to reevaluate our study designs and endpoints in MDS.
With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1